There's a Politics forum? That must be fun. Van- Watch BCRX-!!! We own it!~ NIAID awards BioCryst $44M contract to advance galidesivir development 09:31 BCRX BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded BioCryst a new contract totaling $44M, and has added approximately $3M to its existing contract, to support the development of galidesivir. The additional funds under these performance-based contracts support: The completion of parts 1 and 2 of an ongoing clinical trial of galidesivir in Brazil; Conducting a phase 2 clinical trial of galidesivir in non-hospitalized COVID-19 patients at high risk for developing severe disease and complications of COVID-19; Conducting a clinical pharmacology trial of galidesivir to determine appropriate dosing in patients with renal impairment; Increasing the supply of galidesivir. Galidesivir is an investigational broad-spectrum antiviral drug that was safe and well tolerated in previous phase 1 trials in healthy subjects. Galidesivir has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including the coronaviruses that cause MERS and SARS. The review of unblinded data from part 1 of an ongoing phase 1 trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19, and a decision to choose a dose and advance into part 2 of the trial, are expected to occur in the fourth quarter of 2020. Additionally, non-human primate studies and supporting in vitro studies are underway to assess the activity of galidesivir against SARS-CoV-2, the virus that causes COVID-19. The galidesivir development program is substantially funded with federal funds from NIAID and by Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. Since September 2013, NIAID has supported BioCryst in developing galidesivir as broad-spectrum antiviral therapeutic under contract HHSN272201300017C. Since March 2015, BARDA has supported the galidesivir development program under contract HHSO100201500007C for the continued development of galidesivir as a potential broad- spectrum antiviral treatment for filoviruses. In addition to the new contract award from NIAID, there is currently approximately $27 million remaining on the existing BARDA contract.<----
Aug. 4, 2020 11:20 AM ET|About: Sintx Technologies, Inc. (SINT)|By: OEM company O2TODAY, develops and commercializes face masks for medical and non-medical applications signed a joint development agreement with SINTX Technologies (SINT +21.8%) to develop a safe and effective consumer facemask with broad-spectrum antibacterial and antiviral activity. It will be based on incorporating SINTX’s unique silicon nitride powder into the mask filter and fabric for prevention of respiratory diseases. Both the companies will jointly fund collaborative research and product development activities in Salt Lake City, Utah, with the input of external laboratories also. As per a commercialization agreement, O2TODAY will be the exclusive global distributor for face masks & replacement filters. /// Today News--UP 15% on rumors... SINT.
BioRxiv posts pre-print article on Sintx Technologies' SARS-CoV-2 candidate-- I don't have the story...
So that's a test tube experiment in a test called for by the company. Lots of stuff kills Covid in a test tube that cannot go into the body. Normally we would just discard this idea but the coating that they can apply to face masks.. that's actually quite interesting. It must pass health and safety in that regard it can be worn net to the skin so there is potentially a huge market for a spray which you cover everything with.. like a talcum powder... well you know where that got J&J....
I set a volume alert on OSUR. I like it but we can wait for a move. SWBI is almost a proxy for election betting odds. I think its topped. In short at 18.40 for a quickie EDIT...... ahhh... I'm out at 18.32. You should have mentioned it last week